Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

ResMed (RMD) Financials

ResMed logo
$285.76 -7.97 (-2.71%)
Closing price 03:59 PM Eastern
Extended Trading
$285.84 +0.08 (+0.03%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for ResMed

Annual Income Statements for ResMed

This table shows ResMed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 353 352 342 316 405 622 475 779 898 1,021 1,401
Consolidated Net Income / (Loss)		 353 352 342 316 405 622 475 779 898 1,021 1,401
Net Income / (Loss) Continuing Operations		 353 352 342 316 405 622 475 779 898 1,021 1,401
Total Pre-Tax Income 		436 440 419 521 519 733 884 960 1,102 1,265 1,678
Total Operating Income		 409 429 426 542 579 810 904 1,000 1,132 1,320 1,685
Total Gross Profit		 1,011 1,066 1,202 1,335 1,494 1,718 1,839 2,024 2,356 2,655 3,055
Total Revenue		 1,679 1,839 2,067 2,340 2,607 2,957 3,197 3,578 4,223 4,685 5,146
Total Cost of Revenue		 668 772 865 1,005 1,113 1,239 1,358 1,554 1,867 2,030 2,091
Operating Cost of Revenue		 668 772 865 1,005 1,113 1,239 1,358 1,554 1,867 2,030 2,091
Total Operating Expenses		 602 638 776 793 915 908 935 1,024 1,224 1,335 1,370
Selling, General & Admin Expense		 479 488 554 600 645 677 670 738 874 917 991
Research & Development Expense		 115 119 144 155 181 202 225 254 288 308 331
Amortization Expense		 8.67 24 47 19 32 30 31 31 42 47 45
Total Other Income / (Expense), net		 27 11 -7.06 -21 -60 -77 -20 -40 -30 -55 -7.80
Interest & Investment Income		 26 17 17 16 -14 -25 -11 -31 -55 -48 3.64
Other Income / (Expense), net		 6.25 4.96 4.10 -8.54 -11 -12 15 -9.01 24 -7.54 -16
Income Tax Expense		 83 87 76 206 114 111 409 181 204 244 277
Basic Earnings per Share		 $2.51 $2.51 $2.42 $2.21 $2.83 $4.31 $3.27 $5.34 $6.12 $6.94 $9.55
Weighted Average Basic Shares Outstanding		 140.47M 140.24M 141.36M 142.76M 143.11M 144.34M 145.31M 146.07M 146.77M 147.02M 146.72M
Diluted Earnings per Share		 $2.47 $2.49 $2.40 $2.19 $2.80 $4.27 $3.24 $5.30 $6.09 $6.92 $9.51
Weighted Average Diluted Shares Outstanding		 142.69M 141.67M 142.45M 143.99M 144.48M 145.65M 146.45M 147.04M 147.46M 147.55M 147.34M
Weighted Average Basic & Diluted Shares Outstanding		 140.60M 140.40M 141.40M 142.80M 143M 144.90M 145.68K 146.42M 147.07M 146.93M 146.41M
Cash Dividends to Common per Share		 $1.12 $1.20 $1.32 $1.40 $1.48 $1.56 $1.56 $1.68 $1.76 $1.92 $2.12

Quarterly Income Statements for ResMed

This table shows ResMed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 225 233 230 219 209 300 292 311 345 365 380
Consolidated Net Income / (Loss)		 225 233 230 219 209 300 292 311 345 365 380
Net Income / (Loss) Continuing Operations		 225 233 230 219 209 300 292 311 345 365 380
Total Pre-Tax Income 		274 289 277 272 259 375 358 383 418 418 458
Total Operating Income		 280 301 275 289 275 375 381 387 417 426 455
Total Gross Profit		 580 618 617 600 647 693 716 717 751 766 820
Total Revenue		 1,034 1,117 1,122 1,102 1,163 1,197 1,223 1,225 1,282 1,292 1,348
Total Cost of Revenue		 454 499 505 502 516 504 508 507 531 525 528
Operating Cost of Revenue		 454 499 505 502 516 504 508 507 531 525 528
Total Operating Expenses		 300 317 342 311 372 318 334 330 334 340 366
Selling, General & Admin Expense		 212 228 240 223 222 230 242 239 242 245 265
Research & Development Expense		 70 76 78 76 74 77 81 80 81 84 86
Amortization Expense		 9.56 12 12 12 12 11 11 11 11 11 12
Total Other Income / (Expense), net		 -6.50 -11 1.54 -17 -16 0.84 -23 -3.82 1.08 -8.58 3.51
Interest & Investment Income		 -2.83 -0.18 -50 -19 -13 -11 -45 0.96 1.08 0.34 1.27
Other Income / (Expense), net		 6.66 3.85 19 2.05 -2.57 11 -18 -3.12 0.78 -9.70 -3.51
Income Tax Expense		 49 57 47 53 51 75 65 72 74 53 78
Basic Earnings per Share		 $1.53 $1.58 $1.57 $1.49 $1.42 $2.04 $1.99 $2.12 $2.35 $2.49 $2.59
Weighted Average Basic Shares Outstanding		 146.70M 146.91M 146.77M 147.08M 147.13M 146.96M 147.02M 146.86M 146.81M 146.72M 146.72M
Diluted Earnings per Share		 $1.53 $1.58 $1.55 $1.49 $1.42 $2.04 $1.97 $2.11 $2.34 $2.48 $2.58
Weighted Average Diluted Shares Outstanding		 147.41M 147.40M 147.46M 147.49M 147.55M 147.45M 147.55M 147.60M 147.48M 147.22M 147.34M
Weighted Average Basic & Diluted Shares Outstanding		 146.91M 146.93M 147.07M 147.09M 147.09M 146.91M 146.93M 146.80M 146.87M 146.63M 146.41M
Cash Dividends to Common per Share		 $0.44 $0.44 $0.44 $0.48 $0.48 $0.48 $0.48 $0.53 $0.53 $0.53 $0.53

Annual Cash Flow Statements for ResMed

This table details how cash moves in and out of ResMed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents		 -163 14 91 -633 -42 316 -168 -22 -46 10 971
Net Cash From Operating Activities		 409 548 414 505 459 802 737 351 693 1,401 1,752
Net Cash From Continuing Operating Activities		 409 548 414 505 459 802 737 351 693 1,401 1,752
Net Income / (Loss) Continuing Operations		 353 352 342 316 405 622 475 779 898 1,021 1,401
Consolidated Net Income / (Loss)		 353 352 342 316 405 622 475 779 898 1,021 1,401
Depreciation Expense		 73 87 112 120 151 155 157 160 165 177 198
Amortization Expense		 - - - 0.00 0.00 27 35 34 32 39 37
Non-Cash Adjustments To Reconcile Net Income		 48 50 39 60 81 97 69 86 60 119 98
Changes in Operating Assets and Liabilities, net		 -65 59 -80 9.47 -177 -98 1.41 -708 -462 45 17
Net Cash From Investing Activities		 -143 -1,126 -82 -102 -1,076 -180 -158 -230 -1,160 -270 -200
Net Cash From Continuing Investing Activities		 -143 -1,126 -82 -102 -1,076 -180 -158 -230 -1,160 -270 -200
Purchase of Property, Plant & Equipment		 -63 -59 -62 -63 -69 -95 -103 -135 -120 -99 -90
Acquisitions		 -39 -1,051 -17 -9.78 -960 -39 -53 -64 -1,027 -149 -150
Purchase of Investments		 -42 -8.97 -6.46 -29 -47 -32 -22 -21 -32 -13 -6.42
Sale and/or Maturity of Investments		 - -7.10 3.32 - - -14 19 -10 19 -8.70 46
Net Cash From Financing Activities		 -256 613 -263 -1,027 581 -317 -765 -128 423 -1,119 -606
Net Cash From Continuing Financing Activities		 -256 613 -263 -1,027 581 -317 -765 -128 423 -1,119 -606
Repayment of Debt		 -182 -284 -545 -1,146 -712 -1,284 -612 -166 -405 -835 -40
Repurchase of Common Equity		 -160 -102 - -54 -23 - - 0.00 0.00 -150 -300
Payment of Dividends		 -158 -169 -198 -200 -213 -225 -230 -245 -261 -284 -312
Issuance of Debt		 180 1,140 450 350 1,519 1,190 90 288 1,070 105 0.00
Issuance of Common Equity		 39 28 38 39 37 48 38 47 49 53 74
Other Financing Activities, net		 25 - -8.16 -15 -28 -46 -50 -52 -31 -8.76 -29
Effect of Exchange Rate Changes		 -173 -21 21 -9.74 -5.56 11 18 -14 -2.15 -1.72 26
Cash Interest Paid		 - 11 28 28 36 40 24 22 47 46 28
Cash Income Taxes Paid		 49 69 93 171 243 180 221 478 217 278 214

Quarterly Cash Flow Statements for ResMed

This table details how cash moves in and out of ResMed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Change in Cash & Equivalents		 46 -25 -0.00 -19 1.15 28 0.45 188 96 411 277
Net Cash From Operating Activities		 129 283 237 286 273 402 440 326 309 579 539
Net Cash From Continuing Operating Activities		 129 283 237 286 273 402 440 326 309 579 539
Net Income / (Loss) Continuing Operations		 225 233 230 219 209 300 292 311 345 365 380
Consolidated Net Income / (Loss)		 225 233 230 219 209 300 292 311 345 365 380
Depreciation Expense		 38 44 47 45 45 43 44 45 46 44 64
Amortization Expense		 7.77 8.43 8.44 8.51 8.59 11 11 8.98 9.46 8.24 11
Non-Cash Adjustments To Reconcile Net Income		 11 12 16 23 54 6.08 36 20 23 29 26
Changes in Operating Assets and Liabilities, net		 -153 -14 -63 -9.59 -44 41 57 -59 -115 132 59
Net Cash From Investing Activities		 -1,026 -28 -47 -149 -41 -33 -47 2.15 -37 -32 -134
Net Cash From Continuing Investing Activities		 -1,026 -28 -47 -149 -41 -33 -47 2.15 -37 -32 -134
Purchase of Property, Plant & Equipment		 -27 -29 -34 -30 -23 -21 -25 -18 -21 -21 -31
Acquisitions		 -996 -2.41 -5.81 -114 -8.71 -5.00 -21 -1.77 -3.50 -2.99 -142
Purchase of Investments		 -13 -13 -2.50 -3.68 -3.63 -2.39 -3.07 18 -20 -2.05 -2.01
Sale and/or Maturity of Investments		 10 16 -3.77 -1.25 -5.46 -4.58 2.58 4.13 7.42 -5.95 41
Net Cash From Financing Activities		 933 -280 -189 -151 -239 -336 -393 -151 -148 -144 -164
Net Cash From Continuing Financing Activities		 933 -280 -189 -151 -239 -336 -393 -151 -148 -144 -164
Repayment of Debt		 -15 -215 -145 -185 -130 -220 -300 -30 -5.00 - -5.00
Repurchase of Common Equity		 - - - 0.00 -50 -50 -50 -50 -75 -75 -100
Payment of Dividends		 -65 -65 -67 -72 -71 -70 -72 -79 -78 -78 -78
Issuance of Common Equity		 22 0.98 23 0.98 20 4.89 28 8.38 27 9.02 30
Other Financing Activities, net		 -30 -0.90 -0.02 -0.23 -7.80 -0.31 0.87 -0.39 -17 -0.36 -11
Effect of Exchange Rate Changes		 11 -0.21 -2.33 -4.96 8.42 -5.30 0.13 11 -29 7.96 36
Cash Interest Paid		 10 15 15 15 14 11 5.92 7.35 -0.07 14 6.91
Cash Income Taxes Paid		 55 38 71 77 97 62 43 106 119 -27 16

Annual Balance Sheets for ResMed

This table presents ResMed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Total Assets		 2,182 3,257 3,468 3,064 4,108 4,587 4,728 5,096 6,752 6,872 8,174
Total Current Assets		 1,408 1,420 1,644 1,066 1,145 1,523 1,575 1,931 2,368 2,358 3,506
Cash & Equivalents		 717 731 822 189 147 463 295 274 228 238 1,209
Accounts Receivable		 363 382 451 484 528 475 614 576 705 837 939
Inventories, net		 247 224 268 269 350 417 457 744 998 822 928
Prepaid Expenses		 81 82 103 125 120 75 208 338 437 460 429
Plant, Property, & Equipment, net		 388 384 394 387 387 417 463 498 538 548 551
Total Noncurrent Assets		 386 1,453 1,430 1,612 2,575 2,647 2,690 2,666 3,846 3,967 4,118
Goodwill		 264 1,059 1,065 1,069 1,856 1,890 1,928 1,936 2,770 2,842 3,047
Intangible Assets		 47 300 262 215 522 448 393 346 552 486 465
Noncurrent Deferred & Refundable Income Taxes		 46 55 62 54 45 41 80 80 133 204 253
Other Noncurrent Operating Assets		 28 38 42 274 151 267 289 304 390 435 353
Total Liabilities & Shareholders' Equity		 2,182 3,257 3,468 3,064 4,108 4,587 4,728 5,096 6,752 6,872 8,174
Total Liabilities		 594 1,562 1,508 1,005 2,035 2,090 1,842 1,735 2,622 2,008 2,207
Total Current Liabilities		 266 638 360 511 556 603 912 689 759 911 1,019
Short-Term Debt		 - 299 - 11 12 12 12 9.92 9.90 9.90 9.90
Accounts Payable		 81 93 93 93 116 136 138 159 151 238 278
Accrued Expenses		 133 157 186 186 266 270 321 345 366 378 402
Current Deferred Revenue		 36 50 52 61 89 99 110 109 138 153 166
Current Deferred & Payable Income Tax Liabilities		 16 39 29 160 73 65 308 45 72 108 132
Other Current Liabilities		 - - - - 0.00 21 24 22 22 25 31
Total Noncurrent Liabilities		 328 924 1,148 494 1,479 1,488 931 1,046 1,863 1,098 1,187
Long-Term Debt		 301 873 1,079 270 1,259 1,164 643 765 1,431 697 658
Noncurrent Deferred Revenue		 21 40 53 210 207 200 154 144 156 137 157
Noncurrent Deferred & Payable Income Tax Liabilities		 6.37 9.06 14 13 11 13 11 9.71 91 79 78
Other Noncurrent Operating Liabilities		 0.00 1.21 2.43 0.92 2.06 110 122 126 185 184 295
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,587 1,695 1,960 2,059 2,072 2,497 2,886 3,361 4,130 4,864 5,968
Total Preferred & Common Equity		 1,587 1,695 1,960 2,059 2,072 2,497 2,886 3,361 4,130 4,864 5,968
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,587 1,695 1,960 2,059 2,072 2,497 2,886 3,361 4,130 4,864 5,968
Common Stock		 1,229 1,304 1,380 1,451 1,512 1,571 1,623 1,683 1,773 1,897 2,034
Retained Earnings		 1,976 2,160 2,316 2,432 2,436 2,833 3,080 3,614 4,253 4,992 6,081
Treasury Stock		 -1,445 -1,547 -1,547 -1,600 -1,623 -1,623 -1,623 -1,623 -1,623 -1,773 -2,073
Accumulated Other Comprehensive Income / (Loss)		 -174 -223 -189 -224 -253 -284 -193 -313 -273 -252 -75

Quarterly Balance Sheets for ResMed

This table presents ResMed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Total Assets		 5,178 6,676 6,714 6,752 6,741 6,905 6,815 6,872 7,222 7,141 7,567
Total Current Assets		 2,034 2,325 2,338 2,368 2,305 2,378 2,351 2,358 2,641 2,836 3,208
Cash & Equivalents		 207 253 228 228 209 210 238 238 426 522 933
Accounts Receivable		 620 672 686 705 692 730 779 837 811 860 908
Inventories, net		 865 989 1,011 998 958 933 829 822 918 882 863
Prepaid Expenses		 341 411 412 437 445 505 505 460 486 572 505
Plant, Property, & Equipment, net		 487 523 529 538 534 552 540 548 560 520 535
Total Noncurrent Assets		 2,656 3,828 3,847 3,846 3,902 3,975 3,924 3,967 4,021 3,785 3,823
Goodwill		 1,939 2,767 2,784 2,770 2,812 2,862 2,836 2,842 2,886 2,805 2,849
Intangible Assets		 338 587 570 552 563 528 501 486 479 438 430
Noncurrent Deferred & Refundable Income Taxes		 81 86 96 133 138 156 162 204 221 209 217
Other Noncurrent Operating Assets		 299 388 398 390 389 429 424 435 436 332 327
Total Liabilities & Shareholders' Equity		 5,178 6,676 6,714 6,752 6,741 6,905 6,815 6,872 7,222 7,141 7,567
Total Liabilities		 1,745 2,938 2,781 2,622 2,490 2,423 2,185 2,008 2,027 1,888 2,021
Total Current Liabilities		 693 733 762 759 771 764 773 911 904 852 941
Short-Term Debt		 9.91 9.90 9.90 9.90 9.91 9.90 9.90 9.90 9.90 9.91 9.91
Accounts Payable		 181 196 162 151 177 202 177 238 249 220 223
Accrued Expenses		 324 312 347 366 348 332 356 378 366 353 386
Current Deferred Revenue		 108 134 141 138 147 149 151 153 157 157 160
Current Deferred & Payable Income Tax Liabilities		 48 58 78 72 67 47 55 108 94 85 133
Other Current Liabilities		 21 22 23 22 22 24 24 25 28 28 29
Total Noncurrent Liabilities		 1,052 2,205 2,020 1,863 1,720 1,659 1,412 1,098 1,123 1,036 1,080
Long-Term Debt		 785 1,791 1,576 1,431 1,352 1,217 997 697 668 663 663
Noncurrent Deferred Revenue		 135 140 146 156 134 140 144 137 144 147 151
Noncurrent Deferred & Payable Income Tax Liabilities		 12 108 113 91 88 89 87 79 84 77 79
Other Noncurrent Operating Liabilities		 120 167 185 185 147 214 184 184 228 150 187
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3,433 3,738 3,933 4,130 4,250 4,482 4,630 4,864 5,195 5,253 5,546
Total Preferred & Common Equity		 3,433 3,738 3,933 4,130 4,250 4,482 4,630 4,864 5,195 5,253 5,546
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3,433 3,738 3,933 4,130 4,250 4,482 4,630 4,864 5,195 5,253 5,546
Common Stock		 1,702 1,711 1,730 1,773 1,792 1,824 1,849 1,897 1,925 1,958 1,991
Retained Earnings		 3,760 3,920 4,088 4,253 4,402 4,540 4,770 4,992 5,225 5,492 5,779
Treasury Stock		 -1,623 -1,623 -1,623 -1,623 -1,623 -1,673 -1,723 -1,773 -1,823 -1,898 -1,973
Accumulated Other Comprehensive Income / (Loss)		 -406 -270 -262 -273 -320 -208 -265 -252 -132 -299 -251

Annual Metrics And Ratios for ResMed

This table displays calculated financial ratios and metrics derived from ResMed's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 7.97% 9.52% 12.40% 13.23% 11.38% 13.44% 8.11% 11.93% 18.02% 10.95% 9.84%
EBITDA Growth		 1.90% 6.59% 4.09% 20.51% 10.12% 36.08% 13.40% 6.77% 14.24% 12.90% 24.67%
EBIT Growth		 2.34% 4.43% -0.93% 24.05% 6.61% 40.27% 15.17% 7.92% 16.65% 13.50% 27.24%
NOPAT Growth		 2.11% 3.81% 1.21% -5.76% 37.71% 52.00% -29.33% 67.28% 13.60% 15.53% 32.08%
Net Income Growth		 2.20% -0.14% -2.87% -7.80% 28.20% 53.65% -23.67% 64.26% 15.15% 13.75% 37.20%
EPS Growth		 3.35% 0.81% -3.61% -8.75% 27.85% 52.50% -24.12% 63.58% 14.91% 13.63% 37.43%
Operating Cash Flow Growth		 0.31% 34.02% -24.43% 21.97% -9.10% 74.76% -8.17% -52.34% 97.44% 102.11% 25.00%
Free Cash Flow Firm Growth		 52.10% -298.00% 143.00% 47.12% -250.67% 213.51% -33.16% -56.57% -386.21% 292.53% 22.10%
Invested Capital Growth		 1.50% 82.48% 3.78% -2.94% 48.53% 0.44% 1.11% 19.00% 38.34% -0.19% 1.76%
Revenue Q/Q Growth		 2.31% 3.70% 1.88% 2.94% 3.22% 2.26% 3.42% 1.09% 5.16% 2.21% 2.49%
EBITDA Q/Q Growth		 -0.68% 6.03% 1.17% 3.54% -2.48% 15.99% 1.74% -0.02% 4.47% 4.68% 5.99%
EBIT Q/Q Growth		 -0.30% 4.92% 1.21% 3.65% -4.89% 16.43% 2.09% 0.04% 4.31% 5.53% 5.58%
NOPAT Q/Q Growth		 0.76% 0.25% 6.84% 2.56% -5.51% 16.76% 2.68% 1.51% 2.15% 8.42% 4.84%
Net Income Q/Q Growth		 -0.08% -1.22% 5.71% 2.67% -9.20% 21.27% 3.78% -0.01% 4.01% 6.53% 6.66%
EPS Q/Q Growth		 0.41% -0.80% 4.80% 2.82% -9.09% 20.96% 3.51% -0.19% 3.92% 6.46% 6.85%
Operating Cash Flow Q/Q Growth		 -3.90% 8.43% -1.48% -2.11% 2.78% 30.70% -12.34% -29.51% 29.50% 16.91% 5.97%
Free Cash Flow Firm Q/Q Growth		 -9.37% -848.63% 155.72% 14.60% -5.84% 29.79% -17.27% -22.41% 11.31% 23.04% -9.71%
Invested Capital Q/Q Growth		 3.55% 53.62% 0.95% -0.96% -0.45% -2.15% 1.13% 2.78% 1.00% -1.22% 2.65%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 60.24% 58.00% 58.15% 57.04% 57.32% 58.09% 57.53% 56.57% 55.78% 56.67% 59.36%
EBITDA Margin		 29.10% 28.32% 26.23% 27.91% 27.60% 33.10% 34.72% 33.12% 32.06% 32.62% 37.03%
Operating Margin		 24.38% 23.33% 20.60% 23.15% 22.22% 27.38% 28.27% 27.96% 26.80% 28.17% 32.75%
EBIT Margin		 24.75% 23.60% 20.80% 22.79% 21.81% 26.97% 28.73% 27.70% 27.38% 28.01% 32.45%
Profit (Net Income) Margin		 21.02% 19.17% 16.56% 13.49% 15.52% 21.02% 14.84% 21.78% 21.25% 21.79% 27.22%
Tax Burden Percent		 80.95% 80.17% 81.74% 60.54% 77.98% 84.80% 53.70% 81.15% 81.47% 80.72% 83.50%
Interest Burden Percent		 104.92% 101.30% 97.41% 97.75% 91.26% 91.92% 96.21% 96.89% 95.27% 96.38% 100.46%
Effective Tax Rate		 19.05% 19.83% 18.26% 39.46% 22.02% 15.20% 46.30% 18.85% 18.53% 19.28% 16.50%
Return on Invested Capital (ROIC)		 28.51% 20.80% 15.99% 15.02% 16.89% 21.44% 15.03% 22.84% 20.04% 19.96% 26.16%
ROIC Less NNEP Spread (ROIC-NNEP)		 24.28% 89.76% 14.34% 7.91% 9.15% 14.37% 13.03% 15.34% 17.16% 14.67% 44.17%
Return on Net Nonoperating Assets (RNNOA)		 -7.41% 0.67% 2.74% 0.69% 2.69% 5.77% 2.60% 2.12% 3.93% 2.74% -0.29%
Return on Equity (ROE)		 21.10% 21.47% 18.73% 15.70% 19.59% 27.21% 17.63% 24.96% 23.96% 22.70% 25.86%
Cash Return on Invested Capital (CROIC)		 27.02% -37.60% 12.28% 18.00% -22.16% 21.00% 13.93% 5.49% -12.14% 20.15% 24.41%
Operating Return on Assets (OROA)		 18.29% 15.96% 12.78% 16.33% 15.86% 18.34% 19.72% 20.18% 19.52% 19.27% 22.19%
Return on Assets (ROA)		 15.54% 12.96% 10.18% 9.66% 11.28% 14.30% 10.19% 15.87% 15.15% 14.99% 18.62%
Return on Common Equity (ROCE)		 21.10% 21.47% 18.73% 15.70% 19.59% 27.21% 17.63% 24.96% 23.96% 22.70% 25.86%
Return on Equity Simple (ROE_SIMPLE)		 22.23% 20.79% 17.46% 15.33% 19.52% 24.90% 16.44% 23.19% 21.73% 20.99% 0.00%
Net Operating Profit after Tax (NOPAT)		 331 344 348 328 452 687 485 812 922 1,065 1,407
NOPAT Margin		 19.73% 18.70% 16.84% 14.02% 17.33% 23.22% 15.18% 22.69% 21.84% 22.74% 27.34%
Net Nonoperating Expense Percent (NNEP)		 4.23% -68.96% 1.65% 7.11% 7.75% 7.07% 2.00% 7.50% 2.87% 5.29% -18.01%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - - 21.21%
Cost of Revenue to Revenue		 39.76% 42.00% 41.85% 42.96% 42.68% 41.91% 42.47% 43.43% 44.22% 43.33% 40.64%
SG&A Expenses to Revenue		 28.51% 26.54% 26.80% 25.65% 24.75% 22.88% 20.97% 20.61% 20.70% 19.57% 19.26%
R&D to Revenue		 6.84% 6.45% 6.99% 6.63% 6.93% 6.83% 7.05% 7.09% 6.81% 6.56% 6.44%
Operating Expenses to Revenue		 35.87% 34.67% 37.54% 33.89% 35.10% 30.71% 29.26% 28.62% 28.98% 28.50% 26.61%
Earnings before Interest and Taxes (EBIT)		 415 434 430 533 569 798 918 991 1,156 1,312 1,670
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 489 521 542 653 719 979 1,110 1,185 1,354 1,529 1,906
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.45 4.76 5.22 6.76 8.07 10.73 12.09 8.94 7.67 5.77 6.34
Price to Tangible Book Value (P/TBV)		 5.54 24.01 16.15 17.97 0.00 169.08 61.73 27.85 39.26 18.26 15.40
Price to Revenue (P/Rev)		 4.21 4.39 4.95 5.95 6.41 9.06 10.91 8.39 7.50 5.99 7.35
Price to Earnings (P/E)		 20.02 22.88 29.90 44.12 41.31 43.12 73.53 38.54 35.31 27.48 27.01
Dividend Yield		 2.23% 2.09% 2.25% 1.44% 1.27% 0.84% 0.65% 0.82% 0.82% 1.01% 0.82%
Earnings Yield		 5.00% 4.37% 3.34% 2.27% 2.42% 2.32% 1.36% 2.60% 2.83% 3.64% 3.70%
Enterprise Value to Invested Capital (EV/IC)		 5.68 3.98 4.73 6.51 5.58 8.57 10.86 7.91 6.16 5.35 6.87
Enterprise Value to Revenue (EV/Rev)		 3.96 4.63 5.08 5.99 6.84 9.31 11.03 8.53 7.79 6.09 7.25
Enterprise Value to EBITDA (EV/EBITDA)		 13.61 16.33 19.35 21.46 24.80 28.11 31.76 25.77 24.30 18.66 19.57
Enterprise Value to EBIT (EV/EBIT)		 16.00 19.60 24.40 26.29 31.38 34.51 38.38 30.81 28.46 21.73 22.33
Enterprise Value to NOPAT (EV/NOPAT)		 20.07 24.73 30.14 42.74 39.49 40.08 72.65 37.62 35.68 26.77 26.50
Enterprise Value to Operating Cash Flow (EV/OCF)		 16.26 15.52 25.33 27.76 38.86 34.30 47.85 86.97 47.46 20.36 21.29
Enterprise Value to Free Cash Flow (EV/FCFF)		 21.17 0.00 39.25 35.65 0.00 40.92 78.43 156.44 0.00 26.52 28.39
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.19 0.69 0.55 0.14 0.61 0.47 0.23 0.23 0.35 0.15 0.11
Long-Term Debt to Equity		 0.19 0.52 0.55 0.13 0.61 0.47 0.22 0.23 0.35 0.14 0.11
Financial Leverage		 -0.31 0.01 0.19 0.09 0.29 0.40 0.20 0.14 0.23 0.19 -0.01
Leverage Ratio		 1.36 1.66 1.84 1.63 1.74 1.90 1.73 1.57 1.58 1.51 1.39
Compound Leverage Factor		 1.42 1.68 1.79 1.59 1.58 1.75 1.67 1.52 1.51 1.46 1.40
Debt to Total Capital		 15.92% 40.90% 35.49% 12.03% 38.01% 32.02% 18.51% 18.74% 25.87% 12.69% 10.07%
Short-Term Debt to Total Capital		 0.00% 10.44% 0.00% 0.49% 0.36% 0.33% 0.34% 0.24% 0.18% 0.18% 0.15%
Long-Term Debt to Total Capital		 15.92% 30.46% 35.49% 11.54% 37.66% 31.69% 18.17% 18.50% 25.69% 12.52% 9.92%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 84.08% 59.10% 64.51% 87.97% 61.99% 67.98% 81.49% 81.26% 74.13% 87.31% 89.93%
Debt to EBITDA		 0.62 2.25 1.99 0.43 1.77 1.20 0.59 0.65 1.06 0.46 0.35
Net Debt to EBITDA		 -0.85 0.85 0.47 0.14 1.56 0.73 0.32 0.42 0.90 0.31 -0.28
Long-Term Debt to EBITDA		 0.62 1.68 1.99 0.41 1.75 1.19 0.58 0.65 1.06 0.46 0.35
Debt to NOPAT		 0.91 3.41 3.10 0.86 2.81 1.71 1.35 0.96 1.56 0.66 0.47
Net Debt to NOPAT		 -1.26 1.28 0.74 0.28 2.49 1.04 0.74 0.62 1.32 0.44 -0.38
Long-Term Debt to NOPAT		 0.91 2.54 3.10 0.82 2.79 1.70 1.33 0.94 1.55 0.65 0.47
Altman Z-Score		 10.42 5.32 6.45 10.98 7.02 10.02 13.76 13.02 9.61 10.96 13.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.28 2.23 4.57 2.08 2.06 2.53 1.73 2.80 3.12 2.59 3.44
Quick Ratio		 4.05 1.75 3.53 1.32 1.22 1.56 1.00 1.23 1.23 1.18 2.11
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 314 -622 267 393 -592 673 449 195 -559 1,076 1,313
Operating Cash Flow to CapEx		 654.14% 936.09% 665.48% 807.00% 668.10% 841.56% 717.27% 260.43% 579.33% 1,408.87% 1,949.13%
Free Cash Flow to Firm to Interest Expense		 54.33 -55.47 9.47 13.87 -16.39 17.09 19.02 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 70.76 48.90 14.66 17.81 12.70 20.38 31.18 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 59.94 43.67 12.46 15.60 10.80 17.96 26.83 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.74 0.68 0.61 0.72 0.73 0.68 0.69 0.73 0.71 0.69 0.68
Accounts Receivable Turnover		 4.65 4.94 4.96 5.01 5.15 5.90 5.87 6.01 6.59 6.08 5.79
Inventory Turnover		 3.24 3.28 3.51 3.74 3.60 3.23 3.11 2.59 2.14 2.23 2.39
Fixed Asset Turnover		 4.08 4.76 5.31 5.99 6.74 7.35 7.26 7.44 8.15 8.63 9.37
Accounts Payable Turnover		 8.02 8.89 9.33 10.84 10.67 9.85 9.92 10.45 12.05 10.45 8.11
Days Sales Outstanding (DSO)		 78.50 73.91 73.52 72.85 70.87 61.91 62.17 60.71 55.35 60.07 63.01
Days Inventory Outstanding (DIO)		 112.72 111.39 103.97 97.49 101.44 112.89 117.47 141.05 170.24 163.64 152.71
Days Payable Outstanding (DPO)		 45.53 41.05 39.10 33.67 34.19 37.04 36.80 34.91 30.30 34.93 45.02
Cash Conversion Cycle (CCC)		 145.69 144.25 138.39 136.67 138.11 137.76 142.84 166.85 195.30 188.79 170.70
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1,171 2,136 2,217 2,152 3,196 3,210 3,246 3,862 5,343 5,333 5,427
Invested Capital Turnover		 1.44 1.11 0.95 1.07 0.97 0.92 0.99 1.01 0.92 0.88 0.96
Increase / (Decrease) in Invested Capital		 17 966 81 -65 1,044 14 36 617 1,481 -10 94
Enterprise Value (EV)		 6,647 8,505 10,490 14,018 17,839 27,518 35,252 30,537 32,904 28,523 37,289
Market Capitalization		 7,064 8,063 10,233 13,925 16,715 26,805 34,892 30,036 31,691 28,054 37,830
Book Value per Share		 $11.26 $12.07 $13.82 $14.42 $14.45 $17.26 $19.83 $22.97 $28.11 $33.11 $40.70
Tangible Book Value per Share		 $9.05 $2.39 $4.47 $5.43 ($2.14) $1.10 $3.88 $7.37 $5.49 $10.46 $16.75
Total Capital		 1,888 2,868 3,039 2,340 3,343 3,673 3,541 4,136 5,571 5,571 6,636
Total Debt		 301 1,173 1,079 281 1,271 1,176 655 775 1,441 707 668
Total Long-Term Debt		 301 873 1,079 270 1,259 1,164 643 765 1,431 697 658
Net Debt		 -417 441 257 93 1,124 713 360 502 1,213 469 -541
Capital Expenditures (CapEx)		 63 59 62 63 69 95 103 135 120 99 90
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 424 350 462 377 454 470 380 978 1,391 1,219 1,287
Debt-free Net Working Capital (DFNWC)		 1,141 1,081 1,284 566 601 933 675 1,252 1,619 1,457 2,496
Net Working Capital (NWC)		 1,141 782 1,284 554 589 921 663 1,242 1,609 1,447 2,486
Net Nonoperating Expense (NNE)		 -22 -8.51 5.77 12 47 65 11 32 25 44 6.51
Net Nonoperating Obligations (NNO)		 -417 441 257 93 1,124 713 360 502 1,213 469 -541
Total Depreciation and Amortization (D&A)		 73 87 112 120 151 181 192 194 198 216 236
Debt-free, Cash-free Net Working Capital to Revenue		 25.26% 19.02% 22.35% 16.12% 17.43% 15.88% 11.88% 27.34% 32.95% 26.01% 25.01%
Debt-free Net Working Capital to Revenue		 67.98% 58.80% 62.12% 24.18% 23.07% 31.54% 21.11% 34.99% 38.34% 31.10% 48.51%
Net Working Capital to Revenue		 67.98% 42.52% 62.12% 23.69% 22.61% 31.14% 20.74% 34.72% 38.11% 30.89% 48.32%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.51 $2.51 $2.42 $2.21 $2.83 $4.31 $3.27 $5.34 $6.12 $6.94 $9.55
Adjusted Weighted Average Basic Shares Outstanding		 140.47M 140.24M 141.36M 142.76M 143.11M 144.34M 145.31M 146.07M 146.77M 147.02M 146.72M
Adjusted Diluted Earnings per Share		 $2.47 $2.49 $2.40 $2.19 $2.80 $4.27 $3.24 $5.30 $6.09 $6.92 $9.51
Adjusted Weighted Average Diluted Shares Outstanding		 142.69M 141.67M 142.45M 143.99M 144.48M 145.65M 146.45M 147.04M 147.46M 147.55M 147.34M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 140.52M 140.70M 142.21M 142.68M 143.67M 144.90M 145.68K 146.42M 147.07M 146.93M 146.41M
Normalized Net Operating Profit after Tax (NOPAT)		 331 349 373 339 491 686 490 813 939 1,117 1,407
Normalized NOPAT Margin		 19.73% 19.00% 18.06% 14.49% 18.84% 23.20% 15.32% 22.73% 22.23% 23.85% 27.34%
Pre Tax Income Margin		 25.96% 23.91% 20.26% 22.28% 19.91% 24.79% 27.64% 26.84% 26.09% 27.00% 32.60%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 71.91 38.72 15.23 18.81 15.72 20.26 38.87 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 57.34 30.69 12.33 11.57 12.49 17.45 20.54 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 61.09 33.50 13.02 16.60 13.82 17.84 34.53 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 46.52 25.47 10.12 9.36 10.59 15.02 16.19 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 44.69% 48.06% 57.85% 63.37% 52.55% 36.26% 48.52% 31.48% 29.04% 27.78% 22.26%
Augmented Payout Ratio		 90.12% 77.02% 57.85% 80.42% 58.20% 36.26% 48.52% 31.48% 29.04% 42.47% 43.67%

Quarterly Metrics And Ratios for ResMed

This table displays calculated financial ratios and metrics derived from ResMed's official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 15.52% 29.20% 22.66% 16.00% 12.48% 7.17% 9.01% 11.08% 10.26% 7.92% 10.20%
EBITDA Growth		 12.77% 24.93% 19.91% 9.36% -1.96% 23.32% 19.58% 27.12% 45.42% 6.32% 25.81%
EBIT Growth		 17.01% 29.91% 19.41% 7.41% -5.00% 26.76% 23.41% 32.01% 53.39% 7.92% 24.32%
NOPAT Growth		 8.89% 30.37% 9.15% 5.09% -3.85% 24.11% 36.36% 34.98% 55.26% 24.25% 20.99%
Net Income Growth		 11.48% 29.88% 17.74% 4.25% -7.16% 29.24% 27.25% 41.90% 65.05% 21.48% 29.93%
EPS Growth		 11.68% 29.51% 17.42% 4.20% -7.19% 29.11% 27.10% 41.61% 64.79% 21.57% 30.96%
Operating Cash Flow Growth		 -41.50% 140.61% 198.71% 541.00% 112.10% 42.28% 85.36% 13.71% 13.12% 43.93% 22.42%
Free Cash Flow Firm Growth		 -9,614.35% -255.89% -207.51% -371.13% 100.61% 114.82% 125.68% 123.59% 4,977.63% 153.50% -12.03%
Invested Capital Growth		 45.55% 40.79% 38.34% 34.36% 4.03% 2.05% -0.19% 0.80% -1.72% -2.08% 1.76%
Revenue Q/Q Growth		 8.78% 8.04% 0.46% -1.76% 5.49% 2.94% 2.19% 0.11% 4.70% 0.75% 4.36%
EBITDA Q/Q Growth		 5.53% 7.50% -2.28% -1.34% -5.40% 35.21% -5.24% 4.88% 8.22% -1.15% 12.13%
EBIT Q/Q Growth		 5.87% 6.16% -3.47% -1.00% -6.36% 41.64% -6.02% 5.90% 8.80% -0.35% 8.27%
NOPAT Q/Q Growth		 3.86% 4.91% -5.46% 2.01% -4.97% 35.43% 3.87% 0.97% 9.31% 8.38% 1.14%
Net Income Q/Q Growth		 6.86% 3.37% -1.22% -4.46% -4.84% 43.91% -2.75% 6.54% 10.68% 5.93% 4.02%
EPS Q/Q Growth		 6.99% 3.27% -1.90% -3.87% -4.70% 43.66% -3.43% 7.11% 10.90% 5.98% 4.03%
Operating Cash Flow Q/Q Growth		 188.02% 119.66% -15.97% 20.57% -4.70% 47.35% 9.47% -26.03% -5.20% 87.50% -6.89%
Free Cash Flow Firm Q/Q Growth		 -484.03% 9.32% 3.00% 8.29% 100.75% 2,117.28% 68.12% -15.75% 61.69% 10.70% -41.66%
Invested Capital Q/Q Growth		 31.45% 0.09% 1.00% 1.11% 1.77% -1.81% -1.22% 2.12% -0.78% -2.17% 2.65%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 56.08% 55.31% 55.02% 54.44% 55.64% 57.88% 58.50% 58.57% 58.60% 59.33% 60.84%
EBITDA Margin		 32.15% 31.99% 31.12% 31.25% 28.03% 36.81% 34.14% 35.76% 36.96% 36.27% 38.97%
Operating Margin		 27.10% 26.92% 24.53% 26.22% 23.66% 31.29% 31.17% 31.63% 32.54% 33.00% 33.72%
EBIT Margin		 27.75% 27.27% 26.20% 26.40% 23.44% 32.25% 29.66% 31.38% 32.60% 32.25% 33.46%
Profit (Net Income) Margin		 21.76% 20.82% 20.47% 19.91% 17.96% 25.10% 23.89% 25.43% 26.88% 28.26% 28.17%
Tax Burden Percent		 82.18% 80.34% 82.97% 80.61% 80.48% 80.04% 81.69% 81.19% 82.38% 87.39% 82.90%
Interest Burden Percent		 95.41% 95.03% 94.16% 93.52% 95.21% 97.26% 98.61% 99.82% 100.07% 100.27% 101.56%
Effective Tax Rate		 17.82% 19.66% 17.03% 19.39% 19.52% 19.96% 18.31% 18.81% 17.62% 12.61% 17.10%
Return on Invested Capital (ROIC)		 18.80% 19.20% 18.68% 19.62% 15.90% 21.48% 22.35% 22.76% 24.23% 27.11% 26.74%
ROIC Less NNEP Spread (ROIC-NNEP)		 18.28% 18.21% 18.82% 18.07% 14.92% 21.55% 20.07% 22.32% 24.38% 24.16% 18.68%
Return on Net Nonoperating Assets (RNNOA)		 5.40% 4.64% 4.31% 4.09% 4.65% 5.35% 3.75% 3.32% 2.92% 1.21% -0.12%
Return on Equity (ROE)		 24.20% 23.84% 22.98% 23.72% 20.56% 26.84% 26.10% 26.08% 27.16% 28.32% 26.61%
Cash Return on Invested Capital (CROIC)		 -18.12% -13.92% -12.14% -9.51% 13.20% 16.36% 20.15% 20.34% 25.02% 27.23% 24.41%
Operating Return on Assets (OROA)		 18.30% 18.85% 18.68% 19.38% 15.55% 21.86% 20.40% 21.60% 22.87% 22.52% 22.89%
Return on Assets (ROA)		 14.35% 14.39% 14.59% 14.61% 11.91% 17.01% 16.43% 17.51% 18.86% 19.73% 19.27%
Return on Common Equity (ROCE)		 24.20% 23.84% 22.98% 23.72% 20.56% 26.84% 26.10% 26.08% 27.16% 28.32% 26.61%
Return on Equity Simple (ROE_SIMPLE)		 21.65% 21.94% 0.00% 21.33% 19.87% 20.70% 0.00% 21.42% 23.77% 23.68% 0.00%
Net Operating Profit after Tax (NOPAT)		 230 242 228 233 221 300 311 314 344 373 377
NOPAT Margin		 22.27% 21.63% 20.35% 21.13% 19.04% 25.05% 25.46% 25.68% 26.81% 28.84% 27.95%
Net Nonoperating Expense Percent (NNEP)		 0.53% 0.99% -0.15% 1.56% 0.98% -0.06% 2.28% 0.44% -0.15% 2.94% 8.06%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - 3.88% - - - 5.80% 5.99% 5.68%
Cost of Revenue to Revenue		 43.92% 44.69% 44.98% 45.56% 44.36% 42.12% 41.50% 41.43% 41.40% 40.67% 39.16%
SG&A Expenses to Revenue		 20.48% 20.45% 21.38% 20.22% 19.11% 19.21% 19.80% 19.52% 18.85% 18.99% 19.67%
R&D to Revenue		 6.76% 6.84% 6.96% 6.87% 6.35% 6.44% 6.61% 6.49% 6.35% 6.50% 6.41%
Operating Expenses to Revenue		 28.97% 28.39% 30.49% 28.22% 31.98% 26.58% 27.33% 26.94% 26.05% 26.33% 27.12%
Earnings before Interest and Taxes (EBIT)		 287 305 294 291 273 386 363 384 418 417 451
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 332 357 349 344 326 441 418 438 474 468 525
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 8.02 8.06 7.67 5.06 5.59 6.26 5.77 6.90 6.39 5.93 6.34
Price to Tangible Book Value (P/TBV)		 78.05 54.73 39.26 24.60 22.96 22.43 18.26 19.60 16.70 14.50 15.40
Price to Revenue (P/Rev)		 7.97 7.89 7.50 4.92 5.57 6.32 5.99 7.46 6.81 6.55 7.35
Price to Earnings (P/E)		 37.04 36.73 35.31 23.74 28.15 30.25 27.48 32.23 26.88 25.03 27.01
Dividend Yield		 0.84% 0.81% 0.82% 1.23% 1.08% 0.95% 1.01% 0.81% 0.88% 0.92% 0.82%
Earnings Yield		 2.70% 2.72% 2.83% 4.21% 3.55% 3.31% 3.64% 3.10% 3.72% 3.99% 3.70%
Enterprise Value to Invested Capital (EV/IC)		 5.96 6.25 6.16 4.20 4.74 5.51 5.35 6.63 6.24 6.17 6.87
Enterprise Value to Revenue (EV/Rev)		 8.38 8.23 7.79 5.18 5.79 6.49 6.09 7.51 6.84 6.50 7.25
Enterprise Value to EBITDA (EV/EBITDA)		 25.74 25.51 24.30 16.39 18.95 20.38 18.66 22.27 19.05 18.14 19.57
Enterprise Value to EBIT (EV/EBIT)		 30.36 29.82 28.46 19.28 22.45 23.93 21.73 25.70 21.74 20.62 22.33
Enterprise Value to NOPAT (EV/NOPAT)		 37.25 36.62 35.68 24.29 28.21 30.29 26.77 31.49 26.57 24.30 26.50
Enterprise Value to Operating Cash Flow (EV/OCF)		 85.16 61.75 47.46 24.25 24.17 24.83 20.36 25.07 22.84 19.73 21.29
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 36.64 34.04 26.52 32.73 24.73 22.42 28.39
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.48 0.40 0.35 0.32 0.27 0.22 0.15 0.13 0.13 0.12 0.11
Long-Term Debt to Equity		 0.48 0.40 0.35 0.32 0.27 0.22 0.14 0.13 0.13 0.12 0.11
Financial Leverage		 0.30 0.25 0.23 0.23 0.31 0.25 0.19 0.15 0.12 0.05 -0.01
Leverage Ratio		 1.66 1.61 1.58 1.55 1.65 1.58 1.51 1.48 1.44 1.41 1.39
Compound Leverage Factor		 1.58 1.53 1.49 1.45 1.57 1.54 1.49 1.48 1.44 1.42 1.41
Debt to Total Capital		 32.51% 28.74% 25.87% 24.26% 21.49% 17.86% 12.69% 11.54% 11.35% 10.82% 10.07%
Short-Term Debt to Total Capital		 0.18% 0.18% 0.18% 0.18% 0.17% 0.18% 0.18% 0.17% 0.17% 0.16% 0.15%
Long-Term Debt to Total Capital		 32.33% 28.56% 25.69% 24.08% 21.32% 17.69% 12.52% 11.37% 11.19% 10.66% 9.92%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 67.49% 71.26% 74.13% 75.74% 78.51% 82.14% 87.31% 88.46% 88.65% 89.18% 89.93%
Debt to EBITDA		 1.47 1.22 1.06 0.98 0.89 0.69 0.46 0.42 0.38 0.37 0.35
Net Debt to EBITDA		 1.26 1.05 0.90 0.83 0.74 0.53 0.31 0.15 0.09 -0.14 -0.28
Long-Term Debt to EBITDA		 1.46 1.22 1.06 0.98 0.88 0.68 0.46 0.41 0.37 0.37 0.35
Debt to NOPAT		 2.13 1.76 1.56 1.46 1.33 1.02 0.66 0.59 0.53 0.50 0.47
Net Debt to NOPAT		 1.83 1.50 1.32 1.23 1.10 0.78 0.44 0.22 0.12 -0.19 -0.38
Long-Term Debt to NOPAT		 2.12 1.75 1.55 1.45 1.32 1.01 0.65 0.58 0.52 0.49 0.47
Altman Z-Score		 7.94 8.72 9.19 7.16 8.19 10.08 10.51 12.76 12.96 12.04 12.50
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.17 3.07 3.12 2.99 3.11 3.04 2.59 2.92 3.33 3.41 3.44
Quick Ratio		 1.26 1.20 1.23 1.17 1.23 1.32 1.18 1.37 1.62 1.96 2.11
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1,424 -1,291 -1,252 -1,149 8.63 191 322 271 438 485 283
Operating Cash Flow to CapEx		 470.33% 980.55% 689.24% 953.16% 1,168.30% 1,897.18% 1,768.88% 1,824.76% 1,494.98% 2,782.56% 1,761.54%
Free Cash Flow to Firm to Interest Expense		 -137.74 -86.29 0.00 0.00 0.00 17.35 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 12.44 18.88 0.00 0.00 0.00 36.46 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 9.80 16.96 0.00 0.00 0.00 34.54 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.66 0.69 0.71 0.73 0.66 0.68 0.69 0.69 0.70 0.70 0.68
Accounts Receivable Turnover		 6.28 6.72 6.59 6.66 6.43 6.26 6.08 6.39 6.20 5.95 5.79
Inventory Turnover		 2.06 2.09 2.14 2.15 2.10 2.20 2.23 2.17 2.26 2.45 2.39
Fixed Asset Turnover		 7.52 7.71 8.15 8.57 8.38 8.58 8.63 8.79 9.19 9.34 9.37
Accounts Payable Turnover		 9.07 11.26 12.05 10.93 10.15 11.95 10.45 9.55 9.70 10.36 8.11
Days Sales Outstanding (DSO)		 58.11 54.30 55.35 54.77 56.81 58.34 60.07 57.08 58.89 61.31 63.01
Days Inventory Outstanding (DIO)		 177.13 174.32 170.24 169.74 173.49 165.73 163.64 168.26 161.61 149.10 152.71
Days Payable Outstanding (DPO)		 40.26 32.41 30.30 33.38 35.96 30.55 34.93 38.23 37.63 35.25 45.02
Cash Conversion Cycle (CCC)		 194.98 196.21 195.30 191.13 194.34 193.52 188.79 187.10 182.86 175.17 170.70
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 5,286 5,290 5,343 5,403 5,498 5,399 5,333 5,446 5,404 5,286 5,427
Invested Capital Turnover		 0.84 0.89 0.92 0.93 0.84 0.86 0.88 0.89 0.90 0.94 0.96
Increase / (Decrease) in Invested Capital		 1,654 1,533 1,481 1,382 213 108 -10 43 -94 -113 94
Enterprise Value (EV)		 31,527 33,055 32,904 22,676 26,085 29,763 28,523 36,120 33,722 32,616 37,289
Market Capitalization		 29,979 31,697 31,691 21,524 25,069 28,994 28,054 35,869 33,571 32,876 37,830
Book Value per Share		 $25.52 $26.77 $28.11 $28.90 $30.47 $31.48 $33.11 $35.36 $35.78 $37.76 $40.70
Tangible Book Value per Share		 $2.62 $3.94 $5.49 $5.95 $7.42 $8.79 $10.46 $12.46 $13.69 $15.44 $16.75
Total Capital		 5,539 5,518 5,571 5,612 5,709 5,637 5,571 5,873 5,926 6,219 6,636
Total Debt		 1,801 1,586 1,441 1,361 1,227 1,007 707 677 673 673 668
Total Long-Term Debt		 1,791 1,576 1,431 1,352 1,217 997 697 668 663 663 658
Net Debt		 1,547 1,358 1,213 1,152 1,016 769 469 251 151 -260 -541
Capital Expenditures (CapEx)		 27 29 34 30 23 21 25 18 21 21 31
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1,349 1,358 1,391 1,335 1,414 1,350 1,219 1,321 1,472 1,345 1,287
Debt-free Net Working Capital (DFNWC)		 1,602 1,586 1,619 1,544 1,624 1,588 1,457 1,747 1,994 2,278 2,496
Net Working Capital (NWC)		 1,592 1,576 1,609 1,534 1,614 1,578 1,447 1,737 1,984 2,268 2,486
Net Nonoperating Expense (NNE)		 5.34 9.07 -1.27 14 13 -0.67 19 3.10 -0.89 7.49 -2.91
Net Nonoperating Obligations (NNO)		 1,547 1,358 1,213 1,152 1,016 769 469 251 151 -260 -541
Total Depreciation and Amortization (D&A)		 46 53 55 53 53 55 55 54 56 52 74
Debt-free, Cash-free Net Working Capital to Revenue		 35.85% 33.82% 32.95% 30.50% 31.39% 29.45% 26.01% 27.47% 29.88% 26.79% 25.01%
Debt-free Net Working Capital to Revenue		 42.58% 39.50% 38.34% 35.28% 36.05% 34.64% 31.10% 36.34% 40.48% 45.36% 48.51%
Net Working Capital to Revenue		 42.32% 39.25% 38.11% 35.06% 35.83% 34.43% 30.89% 36.13% 40.27% 45.16% 48.32%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.53 $1.58 $1.57 $1.49 $1.42 $2.04 $1.99 $2.12 $2.35 $2.49 $2.59
Adjusted Weighted Average Basic Shares Outstanding		 146.70M 146.91M 146.77M 147.08M 147.13M 146.96M 147.02M 146.86M 146.81M 146.72M 146.72M
Adjusted Diluted Earnings per Share		 $1.53 $1.58 $1.55 $1.49 $1.42 $2.04 $1.97 $2.11 $2.34 $2.48 $2.58
Adjusted Weighted Average Diluted Shares Outstanding		 147.41M 147.40M 147.46M 147.49M 147.55M 147.45M 147.55M 147.60M 147.48M 147.22M 147.34M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 146.91M 146.93M 147.07M 147.09M 147.09M 146.91M 146.93M 146.80M 146.87M 146.63M 146.41M
Normalized Net Operating Profit after Tax (NOPAT)		 237 242 228 233 273 300 311 314 344 373 377
Normalized NOPAT Margin		 22.94% 21.63% 20.35% 21.13% 23.48% 25.05% 25.46% 25.68% 26.81% 28.84% 27.95%
Pre Tax Income Margin		 26.48% 25.91% 24.67% 24.69% 22.31% 31.36% 29.25% 31.32% 32.63% 32.34% 33.98%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 27.75 20.35 0.00 0.00 0.00 35.01 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 22.27 16.14 0.00 0.00 0.00 27.19 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 25.10 18.42 0.00 0.00 0.00 33.09 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 19.63 14.22 0.00 0.00 0.00 25.27 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 31.11% 29.56% 29.04% 29.57% 30.80% 29.09% 27.78% 26.10% 23.82% 23.20% 22.26%
Augmented Payout Ratio		 31.11% 29.56% 29.04% 29.57% 36.42% 39.53% 42.47% 44.07% 41.84% 42.24% 43.67%

Key Financial Trends

ResMed (NYSE:RMD) has demonstrated a consistent growth trend in revenue and profitability over the past four years, with sequential quarterly improvements continuing into 2025. The company’s total revenue in Q4 2025 reached approximately $1.35 billion, up from $1.22 billion in Q4 2024, reflecting steady expansion. Net income for Q4 2025 was $380 million, also showing a rising trend versus prior years.

Key positive trends include:

  • Consistent revenue growth each quarter for several years, indicating robust business demand and market presence.
  • Increasing net income and earnings per share (EPS) over the last four years, with Q4 2025 diluted EPS at $2.58 compared to $1.97 in Q4 2024.
  • Strong operating cash flow generation, with Q4 2025 net cash from continuing operating activities of $539 million, supporting financial flexibility.
  • Cash and cash equivalents doubled from around $238 million in Q4 2024 to $933 million in Q3 2025, enhancing liquidity.
  • Controlled operating expenses relative to revenue growth, with gross profit margins stable around 60%, reflecting operational efficiency.
  • Steady dividend payments to shareholders, increasing slightly over time to $0.53 per share in 2025 quarters, underlining commitment to returning capital.

Neutral factors noted:

  • Moderate increases in research & development expense, supporting innovation but increasing cost base.
  • Acquisitions and investments show some variability in cash flow impact, indicating strategic growth initiatives that may require monitoring.
  • Weighted average shares outstanding remain relatively stable, suggesting no significant dilution or share buybacks impact on earnings per share.

Some negative considerations include:

  • Long-term debt levels remain substantial with slight fluctuations, standing at around $663 million in Q3 2025, which could impact leverage and interest costs.
  • Large outflows for acquisitions and investments in certain quarters, such as $1 billion in Q2 2023, which while strategic, represent cash burn and integration risk.
  • Interest and investment income fluctuated significantly, with some quarters showing net expenses on other income, indicating volatility in non-operating items.

Overall, ResMed’s financials indicate solid top-line and bottom-line growth coupled with strong cash flow generation. The company maintains a healthy liquidity position and manages expenses effectively, though continued attention should be given to debt levels and acquisition integration. For retail investors, ResMed shows a stable growth outlook supported by increasing earnings and shareholder returns.

08/25/25 09:39 PMAI Generated. May Contain Errors.

Frequently Asked Questions About ResMed's Financials

When does ResMed's financial year end?

According to the most recent income statement we have on file, ResMed's fiscal year ends in June. Their fiscal year 2025 ended on June 30, 2025.

How has ResMed's net income changed over the last 10 years?

ResMed's net income appears to be on an upward trend, with a most recent value of $1.40 billion in 2025, rising from $352.89 million in 2015. The previous period was $1.02 billion in 2024. See where experts think ResMed is headed by visiting ResMed's forecast page.

What is ResMed's operating income?
ResMed's total operating income in 2025 was $1.69 billion, based on the following breakdown:
  • Total Gross Profit: $3.05 billion
  • Total Operating Expenses: $1.37 billion
How has ResMed's revenue changed over the last 10 years?

Over the last 10 years, ResMed's total revenue changed from $1.68 billion in 2015 to $5.15 billion in 2025, a change of 206.5%.

How much debt does ResMed have?

ResMed's total liabilities were at $2.21 billion at the end of 2025, a 9.9% increase from 2024, and a 271.2% increase since 2015.

How much cash does ResMed have?

In the past 10 years, ResMed's cash and equivalents has ranged from $147.13 million in 2019 to $1.21 billion in 2025, and is currently $1.21 billion as of their latest financial filing in 2025.

How has ResMed's book value per share changed over the last 10 years?

Over the last 10 years, ResMed's book value per share changed from 11.26 in 2015 to 40.70 in 2025, a change of 261.3%.


Related Companies

This page (NYSE:RMD) was last updated on 8/25/2025 by MarketBeat.com Staff
From Our Partners
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...
Priority Gold | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...
Weiss Ratings | Sponsoredtc pixel
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel